developed therapeutic target for metabolic syndrome
Following nuclear testing of one patient a team led by Sergio Leone and Julien Lechat researchers of the Clinical Tumor Unit of Cancer Research of Murcia (CEMCU the IMI Biomechnologies Foundation and CASSM) has shown through analysis of the patients tissue and pathology that an enzyme that is abundant in all human cancers is a great therapeutic target. Prior to the identification of this drug tumors were known to present with high levels of the enzyme called neurexin.
While studies on mouse models of this tumor the results of which have been published in peer-review neurexin and subtype-specific inhibitors have already been tested on patients with breast colon myeloma and neuroblastoma legal restrictions have restricted their use in Los Angeles and Spain. Nevertheless this discovery of this target to be ultimately helpful in metabolic syndromes-and addition confirmed a long-held assumption regarding the effectiveness of targeted therapy-could result in the discovery of new therapies for complex and refractory cancers.
The diseases growths.
Our objective with this project was to identify this targeted therapy which presents a promising therapeutic option for metabolic syndromes including this in breast and colorectal cancer in particular says Sergio Leone researcher of the current project (CEMCUIMI-FRA-CAM-CRITICS CASMAAEE).
Simply put the aim was to determine whether this targeted therapy exhibits physiological activity in cancer cells he continues. In this sense we aimed at understanding the enzymatic activity in each patient so that if this target of cytolysin could be used more effectively with therapeutic success it would be beneficial in the progression of patients with metabolic syndromes.
As part of the investigation we studied the activities of the cytolysin enzymes in the existence of a biochemical model in which tumor cell proliferation cell survival and metabolism were regulated explains Rodrigo Bermudez biochemical researcher of the study. Through this research we have over the past 10 years examined that the number of neurexin enzymes in tumors in patients with cancer was reduced with increasing age in corrected logarithmics. However the effect was not universal in all patients. We verified the percentage of failed protein synthesis and evaluated the medicinal properties of inhibitors with cell lines or in human cells.